The essential role of PD-1 in maintaining immune-tolerance decreases the probability of downregulation of its ligands; therefore, loss of CPR-mediated costimulation is less likely, providing a potential advantage over CART utilizing a tumor antigen as a costimulatory ligand. Here, PDCD1 is linked to neoplasm.